# SCARLET (SWOG S2212)

Source: https://onco.cc/trials/scarlet-s2212/  
OnCo record `scarlet-s2212` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tests whether the anthracycline can be dropped from TNBC pre-surgery treatment without losing effect.

## Summary

SCARLET, SWOG trial S2212, NCT05929768, sponsored by SWOG and the NCI, tests whether the anthracycline can be dropped from pre-surgery treatment of stage II to III triple-negative breast cancer without losing effect, comparing an anthracycline-free regimen of carboplatin, docetaxel and pembrolizumab with the KEYNOTE-522 regimen. It is a non-inferiority trial of 2,400 patients with event-free survival as the primary endpoint, and success would reduce cardiotoxicity and leukaemia risk; it is ongoing with no results. OnCo links it to triple-negative breast cancer, pembrolizumab, carboplatin, the TNBC roadmap, the idea of neoadjuvant ADC plus immunotherapy replacing anthracyclines, the SWOG Cancer Research Network and Priyanka Sharma. Whether de-escalation informed by tumour-infiltrating lymphocytes and pembrolizumab can safely retire anthracyclines is the question it will answer.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-04
- Registry id: NCT05929768
- Phase: 3
- Setting: Stage II-III TNBC: anthracycline-free carboplatin/docetaxel + pembrolizumab vs KEYNOTE-522 regimen
- Sponsor: SWOG / NCI
- Enrolled: 2400
- Replication: Ongoing; no results.

## Sources

- ClinicalTrials.gov NCT05929768: https://clinicaltrials.gov/study/NCT05929768

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [SWOG Cancer Research Network](https://onco.cc/companies/swog/)
- people: [Priyanka Sharma](https://onco.cc/people/priyanka-sharma/)
- key papers: [Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials](https://onco.cc/key-papers/paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012/)
- roadmaps: [Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs](https://onco.cc/roadmaps/chemotherapy-roadmap/), [TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line](https://onco.cc/roadmaps/tnbc-history/), [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- ideas: [Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease](https://onco.cc/ideas/idea-tnbc-de-escalation-for-exceptional-responders/), [Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC](https://onco.cc/ideas/idea-neoadjuvant-adc-io/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)
- trials: [KEYNOTE-522](https://onco.cc/trials/keynote-522/), [NeoPACT](https://onco.cc/trials/neopact/)

---
JSON: https://onco.cc/api/v1/entities/scarlet-s2212.json